Rationale and design of the arterial disease multiple intervention trial (ADMIT) pilot study

American Journal of Cardiology

Volumn 83, Issue 4, 1999, Pages 569-575

  Egan, Debra A ^a   Garg, Rekha ^b   Wilt, Timothy J ^b   Pettinger, Mary B ^b   Davis, Kathryn B ^b   Crouse, John ^b   Herd, J Alan ^b   Hunninghake, Donald B ^b   Sheps, David S ^b   Kostis, John B ^b   Probstfield, Jeffrey ^b   Waclawiw, Myron A ^b   Applegate, William ^b   Elam, Marshall B ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ANTIOXIDANT; ASCORBIC ACID; BIOCHEMICAL MARKER; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PLACEBO; WARFARIN;

ARTERY DISEASE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NIACIN; PERIPHERAL VASCULAR DISEASES; PILOT PROJECTS; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0033557555     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00915-1     Document Type: Article

References (29)

1. Nogues X, Senti M, Pedro-Botet J, Rubies-Prat J, Vidal-Barraquer F. Serum Lipoprotein (a). Levels in men with peripheral vascular disease. [published erratum appears in Angiology 1991 Dec;42:956] Angiology 1991;42:659-664.
2. Senti M, Nogues X, Pedro-Botet J, Rubies-Prat J, Vidal-Barraquer F. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipid proteins and apoprotein E phenotypes. Circulation 1992;85:30-36.
3. Steinberg D, and Workshop Participants. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of an NHLBI Workshop: Sept 5-6, 1991 Circulation 1992;85:2338-2344.
4. Gaziano JM, Manson JE, Buring J, Hennekens CH. Dietary antioxidants and cardiovascular disease. Ann NY Acad Sci 1992;669:249-258.
5. Nachman RL. Blood thrombosis and atherogenesis: molecular connections. 1992;79:1897-1906.
6. McKenna M, Wolfson S, Kuller, L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Athersclerosis 1991;87:119-128.
7. Leng GO, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992;45:1101-1109.
8. National Cholesterol Education Program Expert Panel. Second Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Heart, Lung, and Blood Institute, NIH 1993 (publication no. 93-3095).
9. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, Burrows E, Retziaff B, Poole M. Contrasting effect of unmodified and time-release form of niacin on lipoprotein in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-650.
10. McKenny JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained-VS immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-677.
11. Waters D, Higginson L, Gladstone P, Kimball B, May ML, Boccuzzi SJ, Lesperance J, the CAIT Study Group. Effect of Monotherapy with an HMG-CoA Reductase Inhibitor on the Progression of Coronary Atherosclerosis as Assessed by Serial Quantitative Arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
12. Reaven P, Witztum JL. Lovastatin, nicotinic acid and rhabdomyolysis. Ann Intern Med 1988;109:597-598.
13. Norman DJ, Illingsworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin [Letter]. N Engl J Med 1988;318:46-47.
14. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-1037.
15. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-1456.
16. Kardinaal AFM, Kok FJ, Ringstad J, Gomez-Aracena J, Mazaev VP, Kohlmeier L, Martin BC, Aro A, Kark JD, Delgado-Rodriguez M, Riemersma RA, van'tVeer P, Huttunen JK, Martin-Moreno JM. Antioxidants in adipose tissue and risk of myocardial infarction the EURAMIC study. Lancet 1993;342:1379-1384.
17. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992;3:194-202.
18. Gaziano J, Manson J, Ridker J, Buring J, Hennekens CH. Dietary antioxidants and cardiovascular disease. Biochim Biophys Acta 1992;669:249-258.
19. Jacques P. Effects of vitamin C on high density lipoprotein cholesterol and blood pressure. J Amer Coll Nutr 1992;11:139-144.
20. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smoker. N Engl J Med 1994;330:1029-1035.
21. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993;87:659-675.
22. ESPS Group. The European stroke prevention study (ESPS). Principal end-points. Lancet 1987;2:1351-1354.
23. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
24. Aspirin Myocardial Infarction Study Research Group. A randomized controlled trial of aspirin in person recovered from myocardial infarction. JAMA 1980:243:661-669.
25. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med 1989:321:129-135.
26. Peto R, Gray R, Collins R, Wheatley K, Hennekins C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S. Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J 1988:296:313-316.
27. Tilgren C. Obliterative arterial disease of the lower limbs. IV. Evaluation of long-term anticoagulant therapy. Acta Med Scand 1965:178;203-219.
28. Smith P, Arneson H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990:232:147-152.
29. Peterson P, Godfredsen J, Boysen G, Andersen ED, Anderson B. Placebo controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complications and chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet 1989:1:175-179.